Search
for
Sort by
Research 631–660 of 1000+
- 8273 ACTH-Dependent Cushing's Syndrome Due To Metastatic Cervical Cancer: A Case Report
- Case Report: 8 years old boy with neurofibromatosis type one and Alopecia from KING ABDULAZIZ MEDICAL CITY OF THE NATIONAL GUARD. Saudi Arabia
- LGR5 is a Marker of Poor Prognosis in Glioblastoma and is Required for Survival of Brain Cancer Stem‐Like Cells
- Case Report Vitamin A Toxicity and Hypercalcemia
- Long‐Term Management with Adipose Tissue‐Derived Mesenchymal Stem Cells and Conventional Treatment in a Dog with Hepatocutaneous Syndrome
- Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review
- Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
- A functional role of S100A4/non-muscle myosin IIA axis for pro-tumorigenic vascular functions in glioblastoma
- Ossifying pilomatrixoma with marrow formation of the left cheek region – Case report with review of literature
- Topical Application of Thymidine Dinucleotide to Newborn Mice Reduces and Delays Development of UV-Induced Melanomas
- Review of systemic methotrexate therapy in pediatric dermatoses
- STAT3 Partly Inhibits Cell Proliferation via Direct Negative Regulation of FST Gene Expression
- Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues
- Expression of Plectin-1 and Trichohyalin in Human Tongue Cancer Cells
- Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
- Eclipta prostrata (L.) L.: Traditional Use, Phytochemistry, and Pharmacology
- Niche-dependent immunometabolic regulation of tissue repair and regeneration
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Recent approaches of antibody therapeutics in androgenetic alopecia
- Ectopic Expression of a Truncated Isoform of Hair Keratin 81 in Breast Cancer Alters Biophysical Characteristics to Promote Metastatic Propensity
- Oral Presentation Abstracts
- Hibiscus Rosa Sinensis Linn.
- Enrichment for Living Murine Keratinocytes from the Hair Follicle Bulge with the Cell Surface Marker CD34
- Extraction, Isolation, Characterization, and Biological Activity of Sulfated Polysaccharides Present in Ascidian Viscera Microcosmus exasperatus
- Iodoterapia e seus Efeitos Colaterais no Tratamento de Neoplasia de Tireoide
- Exosomes for Regeneration, Rejuvenation, and Repair
- Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers - A Review
- A Concise Review of Organoid Tissue Engineering: Regenerative Applications and Precision Medicine
- Mesenchymal Stem Cells for Regenerative Medicine